Overseas Third-Generation IVF Hospitals: Real Choices and Process Analysis

Opening: Real Consultation Scenario

Consultation Scenario: A 42-year-old woman with an AMH level of 0.6 ng/mL seeks advice due to repeated implantation failure. She has undergone two IVF cycles domestically without embryo genetic testing. Her core question: "Can overseas third-generation IVF hospitals truly improve success rates? What exactly do I need to prepare?"

Direct Answer to the Question

The core advantage of overseas third-generation IVF hospitals lies in Preimplantation Genetic Testing (PGT), which can screen for chromosomal aneuploidy, structural abnormalities, and monogenic diseases. For patients of advanced maternal age, with recurrent miscarriage, carriers of chromosomal abnormalities, severe male factor, or those with previous PGD indications, PGT can significantly reduce miscarriage rates after transfer and improve live birth rates. However, it is not suitable for everyone — for young patients with normal ovarian function and simple tubal factor infertility, PGT may not increase cumulative live birth rates and may additionally consume embryos and increase cycle costs.

When selecting a hospital, key evaluations include: embryo laboratory qualifications, PGT platform (NGS vs. aCGH), genetic counselor experience, embryologist skill level, and the regulatory system of the country. Differences between hospitals in biopsy timing (day 3 cleavage stage or day 5 trophectoderm cells), cryopreservation and thawing techniques, and blastocyst culture rates directly impact outcomes.

Why Does This Issue Arise

Domestic third-generation IVF is subject to strict indications — both partners must be diagnosed with a genetic disease or chromosomal abnormality, and ethical approval is required. In contrast, some overseas countries (e.g., Thailand, Malaysia, Georgia, and certain US states) have broader indications for PGT, allowing screening for age, repeated failure, or even sex selection. This policy difference leads many patients to view "overseas third-generation" as a universal solution, overlooking medical indications and their own conditions.

Some agencies exaggerate claims like "third-generation IVF success rates up to 80%", but actual data must be stratified by age and etiology: for women under 35 with normal chromosomes, transferring a PGT-A normal blastocyst yields a live birth rate of about 60-65% per single transfer; for women over 42, even with a normal blastocyst, the live birth rate drops to 20-30%. Medically, there is no concept of "guaranteed success".

What Doctors Think

When evaluating applications for overseas third-generation IVF, reproductive specialists first require both partners to undergo a comprehensive fertility assessment: female AMH, antral follicle count (AFC), sex hormone panel (FSH, LH, E2), thyroid function, and uterine cavity evaluation; male semen analysis (including DNA fragmentation index). If AMH is below 0.5 ng/mL and antral follicles are fewer than 3, even with PGT, the number of available embryos is very low. Doctors would recommend prioritizing evaluation of egg or sperm donation options rather than blindly pursuing "third-generation" technology.

For carriers of monogenic diseases (e.g., thalassemia, spinal muscular atrophy), PGT-M (monogenic disease testing) is essential and requires a center with the capability to develop specific probes and provide genetic counseling. Some overseas hospitals cannot customize probes for common mutation sites in the Chinese population, so this needs to be confirmed in advance.

Differences Across Age Groups

Common Pitfalls

• Believing PGT can solve all miscarriage problems: Uterine structural abnormalities, chronic endometritis, and immune disorders (e.g., antiphospholipid syndrome) can also cause miscarriage, and PGT cannot improve these.
• Trusting "non-invasive PGT" or "embryo culture medium testing": The current gold standard remains trophectoderm biopsy (day 5 or 6 blastocyst); non-invasive methods have not been widely validated clinically.
• Ignoring the regulatory environment and data transparency of the hospital's country: Some reproductive centers in certain countries do not publish SART/ESHRE audit reports, making core indicators like usable embryo rate, blastocyst formation rate, and thaw survival rate unverifiable.
• Not verifying genetic counseling qualifications: PGT-M/PGT-SR requires geneticists to interpret results and assess the clinical significance of mosaicism and segmental deletions. Some centers only offer PGT-A and cannot handle complex genetic cases.
• Confusing "live birth rate" with "transfer success rate": Biochemical pregnancy after transfer does not equal live birth. Patients should request the hospital to provide both single-transfer live birth rate and cumulative live birth rate (probability of achieving one live birth from a single egg retrieval cycle).

Actual Process and Timeline

Standard overseas third-generation IVF process (using Thailand/Malaysia as examples):

1. Preparatory Phase (1-2 months): Complete fertility testing for both partners, infectious disease screening (Hepatitis B, Syphilis, HIV, etc.), chromosomal karyotype analysis, and genetic counseling. Some hospitals require certified translations.
2. Ovarian Stimulation (10-14 days): Start gonadotropin injections on day 2-3 of menstruation, monitoring follicle size and hormone levels.
3. Egg Retrieval (30 minutes): Transvaginal ultrasound-guided follicle aspiration, usually under general anesthesia or sedation.
4. Embryo Culture and Biopsy (5-6 days): Blastocysts form by day 5-6 post-retrieval; 3-5 cells are biopsied from the trophectoderm, and the remaining embryos are cryopreserved (vitrification).
5. Genetic Testing (2-4 weeks): NGS platform analysis, reporting chromosomal ploidy and structure. PGT-M requires a longer cycle.
6. Frozen Embryo Transfer Cycle (approx. 4-6 weeks): Thaw and transfer a single normal blastocyst (single embryo transfer recommended). Endometrial preparation (natural cycle or hormone replacement cycle) is required before transfer.
7. Pregnancy Test and Follow-up Care: Blood test for hCG 12-14 days after transfer. Luteal phase support is needed until 8-10 weeks of gestation if pregnancy is confirmed.

The entire cycle from stimulation to transfer completion typically takes about 3-4 months (excluding waiting time and visa processing). If multiple egg retrievals are needed to accumulate embryos, the timeline extends.

Factors Influencing Cost

• Base Medical Fees: Ovarian stimulation medications (imported vs. domestic), egg retrieval and culture, PGT testing (approx. 2000-5000 RMB per embryo, varies).
• Laboratory Technology Differences: Laboratories using time-lapse imaging combined with AI-assisted selection charge higher fees but may reduce unnecessary transfers.
• Nationality and Agency Services: In some countries, medical fees for foreigners are higher than for locals; agencies charge for translation, coordination, and accompaniment (ranging from 20,000 to 80,000 RMB).
• Frozen Embryo Storage Fees: Charged annually, overseas costs approx. 3000-8000 RMB per year.
• Travel and Accommodation: Requires staying at the destination for at least 20-35 days (stimulation + retrieval + transfer), with significant variation in living costs.

Frequently Asked Questions

Handling Special Situations

If all embryos are abnormal after egg retrieval (rare but possible), doctors will suggest discussing the following options: ① Try a different ovarian stimulation protocol (e.g., switching to PPOS protocol or adding growth hormone); ② Consider egg or sperm donation; ③ Transfer mosaic embryos (low-level mosaicism), but only after thorough genetic counseling and risk assessment. Some hospitals freeze mosaic embryos for potential future use but do not prioritize them.

For patients with a history of recurrent implantation failure (RIF), additional tests before transfer should include endometrial receptivity array (ERA), chronic endometritis testing (CD138 immunohistochemistry), and hysteroscopic evaluation. These tests are sometimes more important than PGT itself.

Practitioner Observations

Overseas Coordinator Perspective: We often encounter patients who, after egg retrieval domestically, "only get one 4BC blastocyst" but insist on shipping it overseas for PGT. However, biopsy often yields no result due to DNA contamination or insufficient cells. In reality, top-tier domestic hospitals' reproductive centers have considerable experience with PGT for 4BC blastocysts. Overly pursuing overseas "high-end laboratories" increases transportation risks. The true need for overseas third-generation referral is for genetic diseases restricted by domestic ethics committees, and for families seeking high-precision testing in one go.

End Randomization: Risk Reminder

This article is compiled based on general guidelines in the assisted reproduction industry and real clinical observations. It does not constitute medical advice. Please consult a licensed reproductive specialist for specific plans.